Breaking News Instant updates and real-time market news.

OCUL

Ocular Therapeutix

$6.31

-0.2 (-3.07%)

, REGN

Regeneron

$373.47

-12.58 (-3.26%)

07:06
10/13/16
10/13
07:06
10/13/16
07:06

Ocular Therapeutix outlines strategy for sustained release intravitreal depots

Ocular Therapeutix (OCUL) provided an update on the company's development strategy for its sustained release intravitreal depot technology for the treatment of serious retinal diseases. The company is currently developing proprietary sustained-release hydrogel-based drug delivery depots for intravitreal injection that can be formulated with both small and large molecule pharmaceuticals, such as tyrosine kinase inhibitors and protein-based anti-vascular endothelial growth factors respectively, with the goal of delivering sustained and therapeutic levels of drugs to targeted ocular tissues. The goal of the company's intravitreal depot dual development program is to reduce the frequency of injections that are currently the standard of care for the treatment of wet AMD, DME and other retinal diseases. Accordingly, Ocular Therapeutix also announced today that it has entered into a strategic collaboration, option and license agreement with Regeneron Pharmaceuticals (REGN) for the development of a sustained release formulation of Regeneron's VEGF trap, aflibercept, for the treatment of wet age-related macular degeneration and other serious retinal diseases. Regeneron's aflibercept is currently approved by the U.S. FDA for certain indications under the brand name EYLEA. Per the agreement, Ocular Therapeutix retains all rights to develop its sustained-release hydrogel-based drug delivery platform with all other non-VEGF targeting compounds as well as with small molecule pharmaceuticals, including TKIs, for other retinal diseases.

OCUL

Ocular Therapeutix

$6.31

-0.2 (-3.07%)

REGN

Regeneron

$373.47

-12.58 (-3.26%)

  • 30

    Oct

  • 04

    Nov

  • 29

    Nov

  • 29

    Mar

OCUL Ocular Therapeutix
$6.31

-0.2 (-3.07%)

06/06/16
COWN
06/06/16
NO CHANGE
Target $60
COWN
Outperform
Ocular OTX-DP data miss 'meaningless' to Outperform thesis, says Cowen
Cowen said that while any clinical trial failure of any kind is always a disappointment, the OTX-DP miss in allergic conjunctivitis reported by Ocular Therapeutix is "meaningless" to the firm's thesis, which is predicated "nearly entirely" on the OTX-TP opportunity for the treatment of glaucoma. The firm keeps an Outperform rating and $60 price target on Ocular shares.
06/07/16
MSCO
06/07/16
NO CHANGE
Target $16
MSCO
Overweight
Ocular Therapeutix weakness an overreaction, says Morgan Stanley
Morgan Stanley analyst Andrew Berens said the initial investor reaction to the failure of the second Phase III trial for Dextenza in allergic conjunctivitis appears extreme. Berens said he assigned little direct value for the allergy opportunity and does not see a read through to the post-op indication. The analyst said the focus remains on Dextenza's July 24 PDUFA in post surgical pain and maintains his Overweight rating on Ocular and $16 price target.
07/26/16
RBCM
07/26/16
NO CHANGE
RBCM
Ocular Therapeutix risk/reward still positive, says RBC Capital
After the FDA issued a complete response letter for Ocular's Dextenza, RBC Capital analyst Adnan Butt notes that the agency did not ask for more safety or efficacy data about the drug. According to the analyst, the company has already issued a response to the letter, and the FDA's reply could come in one to three months. Butt thinks that the stock could still advance if Dextenza and a number of its other drugs are approved. The analyst trimmed the price target on the shares to $38 from $40 but keeps an Outperform rating on the stock.
08/11/16
JMPS
08/11/16
INITIATION
Target $21
JMPS
Outperform
Ocular Therapeutix initiated with an Outperform at JMP Securities
Target $21.
REGN Regeneron
$373.47

-12.58 (-3.26%)

09/21/16
RBCM
09/21/16
NO CHANGE
RBCM
Regeneron Fasinumab deal positive, says RBC Capital
After Teva (TEVA) agreed to partner with Regeneron (REGN) on its Fasinumab pain killer, RBC Capital analyst Adrian Butt says that the deal validates the "under the radar" drug. The analyst says that Regeneron could make "many future deals" if its pipeline remains productive. Butt writes that the terms of the deal are attractive for Regeneon, and the analyst keeps a $648 price target and Outperform rating on the stock.
09/21/16
ROTH
09/21/16
NO CHANGE
Target $520
ROTH
Buy
Teva deal important for Regeneron, says at Roth Capital
Roth Capital analyst Joseph Pantginis points out that Regeneron (REGN) has signed a global partnership for fasinumab with Teva (TEVA), which he sees as an important new partnership for the former both on the product development front as well as a significant next step for fasinumab and the anti-NGF class of drugs. The analyst believes Regeneron has solid growth prospects and upside potential, and reiterates a Buy rating and $520 price target on the shares.
10/03/16
ROTH
10/03/16
NO CHANGE
Target $520
ROTH
Buy
Regeneron has 'solid' growth prospects, upside potential, says Roth Capital
After Regeneron (REGN) and Sanofi (SNY) released positive results from their Dupixent Phase 3 trials, SOLO 1 and SOLO in patients with atopic dermatitis, Roth Capital analyst Joseph Pantginis notes that clinical studies of Dupixent for additional atopic and allergic diseases are progressing and says he believes Regeneron's shares are poised for upside on upcoming catalysts. Moreover, the analyst says Regeneron has "solid" growth prospects based on approved and late stage products, deep pipeline, expansion of indications for current products, strong partners, and strong cash management. He reiterates a Buy rating and $520 price target on Regeneron's shares.
10/04/16
JPMS
10/04/16
NO CHANGE
Target $110
JPMS
Overweight
Ophthotech price target raised to $110 from $95 at JPMorgan
JPMorgan analyst Anupam Rama raised his price target for Ophthotech to $110 from $95 citing the elimination of Regeneron (REGN) from the Wet age-related macular degeneration space following its trial failure. Ophthotech closed yesterday down $2.56 to $43.57. The stock is down 20% since last Friday amid mechanism concerns following Regeneron's phase 2 data, Rama tells investors in a research note. The analyst views the weakness in Ophthotech as a buying opportunity. There are important mechanistic differences between the company's Fovista and Regeneron's REGN2176-3, and early phase 1 data for Fovista "are comparatively more compelling," the analyst contends. He points out that the Phase 3 results with Fovista + Lucentis combination therapy are expected this quarter. The analyst keeps an Overweight rating on Ophthotech.

TODAY'S FREE FLY STORIES

PKE

Park Electrochemical

$18.66

0.02 (0.11%)

06:31
06/28/17
06/28
06:31
06/28/17
06:31
Earnings
Park Electrochemical reports Q1 EPS before items 12c, consensus 13c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

CBI

CB&I

$20.02

5.62 (39.03%)

06:28
06/28/17
06/28
06:28
06/28/17
06:28
Recommendations
CB&I analyst commentary  »

Court ruling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TOSBF

Toshiba, also use TOSYY

$2.60

-0.09 (-3.35%)

, TOSYY

Toshiba, also use TOSBF

$15.67

-0.24 (-1.51%)

06:28
06/28/17
06/28
06:28
06/28/17
06:28
Periodicals
Toshiba to file $1B lawsuit against Western Digital, Reuters reports »

Toshiba (TOSBF, TOSYY)…

TOSBF

Toshiba, also use TOSYY

$2.60

-0.09 (-3.35%)

TOSYY

Toshiba, also use TOSBF

$15.67

-0.24 (-1.51%)

WDC

Western Digital

$91.85

-0.81 (-0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KOP

Koppers Holdings

$34.00

-0.7 (-2.02%)

06:22
06/28/17
06/28
06:22
06/28/17
06:22
Upgrade
Koppers Holdings rating change  »

Koppers Holdings upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HRB

H&R Block

$31.34

0.02 (0.06%)

06:18
06/28/17
06/28
06:18
06/28/17
06:18
Conference/Events
H&R Block management to meet with Oppenheimer »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

PFPT

Proofpoint

$84.48

-1.3 (-1.52%)

, SYMC

Symantec

$28.11

-0.75 (-2.60%)

06:18
06/28/17
06/28
06:18
06/28/17
06:18
Recommendations
Proofpoint, Symantec analyst commentary  »

Piper highlights…

PFPT

Proofpoint

$84.48

-1.3 (-1.52%)

SYMC

Symantec

$28.11

-0.75 (-2.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HLI

Houlihan Lokey

$34.48

0.1 (0.29%)

06:18
06/28/17
06/28
06:18
06/28/17
06:18
Conference/Events
Houlihan Lokey management to meet with JMP Securities »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

HAL

Halliburton

$41.53

-0.17 (-0.41%)

06:17
06/28/17
06/28
06:17
06/28/17
06:17
Conference/Events
Halliburton management to meet with Piper Jaffray »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

  • 24

    Jul

FIVE

Five Below

$47.79

-0.545 (-1.13%)

06:16
06/28/17
06/28
06:16
06/28/17
06:16
Conference/Events
Five Below management to meet with Loop Capital »

Field trip to company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

AABA

Altaba

$53.64

-0.67 (-1.23%)

, BABA

Alibaba

$141.53

-1.2 (-0.84%)

06:15
06/28/17
06/28
06:15
06/28/17
06:15
Initiation
Altaba, Alibaba, Yahoo Japan initiated  »

Altaba initiated with an…

AABA

Altaba

$53.64

-0.67 (-1.23%)

BABA

Alibaba

$141.53

-1.2 (-0.84%)

YAHOY

Yahoo Japan

$8.77

0.05 (0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

GIL

Gildan Activewear

$31.44

-0.3 (-0.95%)

06:08
06/28/17
06/28
06:08
06/28/17
06:08
Upgrade
Gildan Activewear rating change  »

Gildan Activewear…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOV

Government Properties

$21.90

-0.425 (-1.90%)

06:07
06/28/17
06/28
06:07
06/28/17
06:07
Syndicate
Government Properties files to sell 25M shares of common stock »

The joint bookrunning…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRNT

Ceragon Networks

06:06
06/28/17
06/28
06:06
06/28/17
06:06
Hot Stocks
Ceragon Networks receives new orders from Tier 1 South Cone operator »

Ceragon Networks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jul

  • 13

    Jul

FDC

First Data

$18.53

-0.18 (-0.96%)

06:06
06/28/17
06/28
06:06
06/28/17
06:06
Downgrade
First Data rating change  »

First Data downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

EGOV

NIC Inc.

$19.00

-0.55 (-2.81%)

06:05
06/28/17
06/28
06:05
06/28/17
06:05
Initiation
NIC Inc. initiated  »

NIC Inc. initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FPO

First Potomac

, GOV

Government Properties

$21.90

-0.425 (-1.90%)

06:02
06/28/17
06/28
06:02
06/28/17
06:02
Hot Stocks
First Potomac to be acquired by Government Properties in $1.4B deal »

First Potomac Realty…

FPO

First Potomac

GOV

Government Properties

$21.90

-0.425 (-1.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

06:01
06/28/17
06/28
06:01
06/28/17
06:01
Technical Analysis
S&P 500: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FPO

First Potomac

, GOV

Government Properties

$21.90

-0.425 (-1.90%)

06:00
06/28/17
06/28
06:00
06/28/17
06:00
Hot Stocks
Breaking Hot Stocks news story on First Potomac, Government Properties »

First Potomac to be…

FPO

First Potomac

GOV

Government Properties

$21.90

-0.425 (-1.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOS

Canada Goose

$21.13

-0.18 (-0.84%)

06:00
06/28/17
06/28
06:00
06/28/17
06:00
Syndicate
Canada Goose 12.5M share Secondary priced at $20.75 »

CIBC, Credit Suisse,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

RGEN

Repligen

$43.25

-2.09 (-4.61%)

05:59
06/28/17
06/28
05:59
06/28/17
05:59
Syndicate
Repligen 2.807M share Spot Secondary priced at $42.75 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

GDX

Market Vector Gold Miners

$22.26

-0.3 (-1.33%)

05:59
06/28/17
06/28
05:59
06/28/17
05:59
Technical Analysis
Market Vector Gold Miners: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLD

SPDR Gold Trust

$118.81

0.45 (0.38%)

05:59
06/28/17
06/28
05:59
06/28/17
05:59
Technical Analysis
SPDR Gold Trust: Pivot points, pivot high broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NUGT

Direxion Gold Miners Bull

$31.50

-1.23 (-3.76%)

05:58
06/28/17
06/28
05:58
06/28/17
05:58
Technical Analysis
Direxion Gold Miners Bull: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TYG

Tortoise Energy

$29.13

-0.14 (-0.48%)

05:58
06/28/17
06/28
05:58
06/28/17
05:58
Upgrade
Tortoise Energy rating change  »

Tortoise Energy upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNUG

Direxion Daily Jr Gld Mnrs Bull 3X Shrs

$18.89

-0.46 (-2.38%)

05:58
06/28/17
06/28
05:58
06/28/17
05:58
Technical Analysis
Direxion Daily Jr Gld Mnrs Bull 3X Shrs: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.